Olmesartan Medoxomil/Amlodipine Teva (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil/Amlodipine Teva, is an angiotensin II receptor blocker (ARB) presented as a fixed‑dose combination for oral use. It treats hypertension, often in adults who require more than one medication to reach blood pressure goals. GNH USA supplies Olmesartan Medoxil/Amlodipine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan Medoxil/Amlodipine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxil/Amlodipine Teva is used in the management of high blood pressure, a condition that involves the renin‑angiotensin system and vascular tone.

- Hypertension: lowers systolic and diastolic blood pressure when monotherapy is insufficient. - Hypertension with concomitant edema: adds vasodilation to reduce fluid retention. - Hypertensive patients at cardiovascular risk: improves overall blood pressure control to reduce long‑term risk. - Resistant hypertension: provides a dual mechanism that may aid patients not controlled on single agents. - Hypertension in older adults: offers a once‑daily regimen that simplifies therapy. - Hypertension with metabolic syndrome: combines an ARB and a calcium‑channel blocker without affecting glucose metabolism.

Olmesartan Medoxil/Amlodipine Teva may cause a range of adverse reactions. Monitoring and reporting are recommended.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness: especially after standing quickly. - Flushing: transient warmth sensation. - Fatigue: general tiredness. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of face, lips or throat. - Severe hypotension: symptomatic low blood pressure. - Hepatic dysfunction: elevated liver enzymes. - Renal impairment: worsening kidney function. - Myocardial infarction: rare but reported in high‑risk patients. - Hyperkalemia: elevated potassium levels.

Before starting Olmesartan Medoxil/Amlodipine Teva, patients should be evaluated for several safety considerations.

- Renal function: assess baseline creatinine and eGFR. - Hepatic function: check liver enzymes in patients with liver disease. - Electrolytes: monitor potassium, especially if on potassium‑sparing diuretics. - Pregnancy: avoid use; drug is contraindicated in the second and third trimesters. - Elderly patients: start at lower dose and monitor for hypotension. - Drug interactions: review concomitant medications for potential additive effects. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmesartan Medoxil/Amlodipine Teva can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade: avoid concurrent ACE inhibitors or other ARBs. - Strong CYP3A4 inhibitors: may increase amlodipine levels (e.g., ketoconazole).

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive effect. - Potassium‑rich supplements or salts: risk of hyper‑kalemia. - NSAIDs: can blunt antihypertensive response and affect renal function. - Lithium: increased lithium levels, requiring serum monitoring. - Simvastatin: amlodipine can raise statin concentrations, increasing myopathy risk.